Abstract: Disclosed are a biological entity for treating brain cancer, in particular glioma, and a vector including the biological entity. The biological entity is a construct including at least anti-tumor transgenes comprised of at least one GluA knockdown agent, and preferably at least two GluA knockdown agents, and preferably further includes a fusogenic protein, and immune response promotors of an anti-PD-1 antibody, an anti-CTLA-4 antibody and an IL12. The vector comprises a wild-type HSV-1 virus wherein the biological entity replaces the ICP 34.5 gene of the wild HSV-1 virus. The vector comprising wild type HSV-1 virus modified with the biological entity shows little negative effect on neurons while showing positive effect against human glioblastoma cells, both separately cultured and in co-cultures of neuronal cells and glioblastoma cells.